SIRS Lab GmbH

Identification of new biomarkers and development of in-vitro diagnostic products for the early detection of inflammatory diseases and bacterial infections in the field of sepsis and critical care medicine.

SIRS-Lab GmbH is a biotechnology company based in Jena, Germany, with expertise knowledge in critical care medicine, assay design, assay development, bio-banking and CE-compliant analysis of clinical samples.

The company has successfully identified a number of biomarker candidates by means of its unique Sepsis-Register bio-sample bank.

Dr. Stefan Russwurm (CEO)
Roberto C. Wolfer (Manager Business Development)

Prof. Dr. Konrad Reinhart
Prof. Dr. Hans-Peter Saluz
Prof. Dr. Eberhard Straube
Prof. Dr. Hans-Peter Deigner

Winzerlaer Str. 2
07745 Jena
Germany
Phone: +49-3641-508-430

SIRS-Lab wants to create value through the development of systems which objectify and automate clinical processes in order to improve the efficiency of clinical intervention as measured against result-oriented standards.

Currently the company pursues the development of three lines of in-vitro diagnostic products.

In 2005, SIRS-Lab launched the product line Looxster(TM) developed on the basis of the specific bacterial DNA binding characteristics of the Pureprove(TM) -Technology. Looxster(TM) increases the sensitivity of nucleic acid-based pathogen detection.